Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.4
4.8
Journals
Biomolecules
Special Issues
Biomarkers in Renal Diseases, 2nd Edition
share announcement

Biomarkers in Renal Diseases, 2nd Edition

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biomarkers".

Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 11091

Special Issue Editors

Prof. Dr. Rosemary Wangensteen

E-Mail Website
Guest Editor
Department of Fisiología, Universidad de Jaén, Jaén, Spain
Interests: kidney health and disease; aminopeptidases; biomarkers
Special Issues, Collections and Topics in MDPI journals
Dr. Antonio Osuna Ortega

E-Mail Website
Guest Editor
Department of Medicine, Faculty of Medicine, University of Granada, 18071 Granada, Spain
Interests: health and disease; uremic toxins; transplantation; biomarkers
Special Issues, Collections and Topics in MDPI journals
Dr. María del Carmen de Gracia Guindo

E-Mail Website
Guest Editor
Nephrology Unit, Universitary Hospital Virgen de las Nieves, 18014 Granada, Spain
Interests: Kidney Health and Disease; chronic kidney disease; transplantation; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Following a very successful first issue, we are pleased to announce the launch of a second edition of Biomarkers in Renal Diseases.

Early detection and monitoring of renal disease remains challenging. Traditional markers such as serum creatinine and proteinuria begin to increase when renal function is already diminished or renal lesions are evident. Therefore, the sensitivity and specificity of these markers may be insufficient for the diagnosis and prognosis of several renal pathologies.

For this Special Issue, we are seeking experimental and clinical articles or reviews concerning biomarkers of acute kidney injury or chronic kidney disease that can increase the sensitivity and specificity of traditional markers, contributing to the early diagnosis of renal diseases and helping to determine a prognosis. Articles may include biomarkers that are present in any biological sample, such as blood, urine, or even extracellular vesicles isolated from urine.

Prof. Dr. Rosemary Wangensteen
Dr. Antonio Osuna Ortega
Dr. María del Carmen de Gracia Guindo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • acute kidney injury
  • chronic kidney disease
  • microvesicles
  • exosomes

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 5275 KiB  
Article
Is Hemopexin a Nephrotoxin or a Marker of Kidney Injury in Renal Ischemia-Reperfusion?
by You Hyun Jeon, Eun-Joo Oh, Se-Hyun Oh, Jeong-Hoon Lim, Hee-Yeon Jung, Ji-Young Choi, Jang-Hee Cho, Sun-Hee Park, Yong-Lim Kim and Chan-Duck Kim
Biomolecules 2024, 14(12), 1522; https://doi.org/10.3390/biom14121522 - 27 Nov 2024
Viewed by 908
Abstract
Destabilization of heme proteins is recognized to play a role in acute kidney injury (AKI). Hemopexin (Hpx), known for its role in binding heme, mitigates free heme toxicity. Despite this, the potential adverse effects of Hpx deposition in kidney tissues and its impact [...] Read more.
Destabilization of heme proteins is recognized to play a role in acute kidney injury (AKI). Hemopexin (Hpx), known for its role in binding heme, mitigates free heme toxicity. Despite this, the potential adverse effects of Hpx deposition in kidney tissues and its impact on kidney function are not fully understood. Deferoxamine (DFO) chelates iron released from heme and mitigates associated kidney damage. Therefore, this study aimed to evaluate whether Hpx contributes to kidney injury in an ischemia-reperfusion injury (IRI) induced AKI model and to investigate if DFO could alleviate this damage. Mice were categorized into five groups: Sham-Vehicle, Sham-Hpx, IRI-Vehicle, IRI-Hpx, and IRI-Hpx-DFO. Decline in kidney function was observed exclusively in the IRI group, independent of Hpx injection. Serum Hpx levels remained comparable across all groups, and administration of Hpx did not alter serum Hpx levels or kidney function after 24 hours. Although increased Hpx deposition in kidneys was noted in both the IRI and Hpx groups, this accumulation did not correlate with impaired kidney function. Additionally, DFO did not exhibit a protective effect against kidney injury. In summary, Hpx does not directly induce kidney injury and cannot be considered a biomarker for kidney damage caused by IRI. Full article
(This article belongs to the Special Issue Biomarkers in Renal Diseases, 2nd Edition)
►▼ Show Figures

Figure 1

15 pages, 4512 KiB  
Article
Aminopeptidasic Enzymes as Early Biomarkers of Cardiac Surgery-Associated Acute Kidney Injury and Long-Term Events
by Noelia Rísquez Chica, Elisa Pereira, Francisco Manzano, María Mar Jiménez Quintana, Antonio Osuna, María Carmen Ruiz Fuentes and Rosemary Wangensteen
Biomolecules 2024, 14(9), 1049; https://doi.org/10.3390/biom14091049 - 24 Aug 2024
Viewed by 1090
Abstract
Background: Diagnosis of acute kidney injury (AKI) relies on serum creatinine (SCr) changes. This study investigated if urinary aminopeptidases are early and predictive biomarkers of cardiac surgery-associated AKI (CSA-AKI). Methods: Glutamyl aminopeptidase (GluAp), alanyl aminopeptidase (AlaAp), dipeptidyl peptidase-4 (DPP4), proteinuria, albuminuria, N-acetyl-β-D [...] Read more.
Background: Diagnosis of acute kidney injury (AKI) relies on serum creatinine (SCr) changes. This study investigated if urinary aminopeptidases are early and predictive biomarkers of cardiac surgery-associated AKI (CSA-AKI). Methods: Glutamyl aminopeptidase (GluAp), alanyl aminopeptidase (AlaAp), dipeptidyl peptidase-4 (DPP4), proteinuria, albuminuria, N-acetyl-β-D-glucosaminidase (NAG), and neutrophile gelatinase-associated lipocalin (NGAL) were measured in urine samples from 44 patients at arrival in the intensive care unit (ICU) after cardiac surgery. Sensitivity, specificity, and positive and negative predictive value for diagnosis of stages 1, 2, and 3 of AKI were analyzed for the highest quartile of each marker. We also studied the relationship with SCr after surgery, 6- and 12-month glomerular filtration rates (GFRs), and other long-term events over the next 5 years. Results: GluAp diagnosed the maximal number of patients that developed stage 2 or 3 of AKI, increasing diagnostic sensitivity from 0% to 75%. In addition, GluAp and DPP4 were related to the decrease in GFR at 6 or 12 months after surgery. Conclusions: Urinary aminopeptidases are a potential tool for the early diagnosis of CSA-AKI, with GluAp being the most effective marker for diagnosing stage 2 or 3 of AKI at ICU admission. GluAp and DPP4 serve as predictive biomarkers for a decrease in GFR. Full article
(This article belongs to the Special Issue Biomarkers in Renal Diseases, 2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 743 KiB  
Review
Toward Precision Medicine: Exploring the Landscape of Biomarkers in Acute Kidney Injury
by Nicole Nourie, Rita Ghaleb, Carmen Lefaucheur and Kevin Louis
Biomolecules 2024, 14(1), 82; https://doi.org/10.3390/biom14010082 - 8 Jan 2024
Cited by 10 | Viewed by 5479
Abstract
Acute kidney injury (AKI) remains a complex challenge with diverse underlying pathological mechanisms and etiologies. Current detection methods predominantly rely on serum creatinine, which exhibits substantial limitations in specificity and poses the issue of late-stage detection of kidney injury. In this review, we [...] Read more.
Acute kidney injury (AKI) remains a complex challenge with diverse underlying pathological mechanisms and etiologies. Current detection methods predominantly rely on serum creatinine, which exhibits substantial limitations in specificity and poses the issue of late-stage detection of kidney injury. In this review, we propose an up-to-date and comprehensive summary of advancements that identified novel biomarker candidates in blood and urine and ideal criteria for AKI biomarkers such as renal injury specificity, mechanistic insight, prognostic capacity, and affordability. Recently identified biomarkers not only indicate injury location but also offer valuable insights into a range of pathological processes, encompassing reduced glomerular filtration rate, tubular function, inflammation, and adaptive response to injury. The clinical applications of AKI biomarkers are becoming extensive and serving as relevant tools in distinguishing acute tubular necrosis from other acute renal conditions. Also, these biomarkers can offer significant insights into the risk of progression to chronic kidney disease CKD and in the context of kidney transplantation. Integration of these biomarkers into clinical practice has the potential to improve early diagnosis of AKI and revolutionize the design of clinical trials, offering valuable endpoints for therapeutic interventions and enhancing patient care and outcomes. Full article
(This article belongs to the Special Issue Biomarkers in Renal Diseases, 2nd Edition)
►▼ Show Figures

Figure 1

16 pages, 2275 KiB  
Review
Biomarkers Associated with Drugs for the Treatment of Lupus Nephritis
by Huiyu Nie, Siyuan Chang, Yuanyuan Li and Fen Li
Biomolecules 2023, 13(11), 1601; https://doi.org/10.3390/biom13111601 - 31 Oct 2023
Cited by 1 | Viewed by 2718
Abstract
The constant updating of lupus drug treatment guidelines has led to a question. How can the efficacy of treatment be more effectively monitored? Systemic lupus erythematosus (SLE) is a complex autoimmune disease that often presents clinically with multi-organ involvement, and approximately 30% of [...] Read more.
The constant updating of lupus drug treatment guidelines has led to a question. How can the efficacy of treatment be more effectively monitored? Systemic lupus erythematosus (SLE) is a complex autoimmune disease that often presents clinically with multi-organ involvement, and approximately 30% of patients with SLE develop lupus nephritis (LN). Therefore, it is important to better track disease progression and drug efficacy. Now, kidney biopsy is still the gold standard for diagnosing and guiding the treatment of LN, but it is invasive and expensive. If simple, non-invasive and effective biomarkers can be found, drug intervention and prognosis can be better monitored and targeted. In this review, we focus on LN and explore biomarkers related to LN therapeutics, providing clinicians with more possibilities to track the therapeutic effect of drugs, improve treatment options and assess patient outcomes. Full article
(This article belongs to the Special Issue Biomarkers in Renal Diseases, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop